2023-10-27 07:04:31
Up to 30 percent of people with severe depression respond poorly to serotonin or serotonin-norepinephrine reuptake inhibitors (SSRI/SNRI). The active ingredient quetiapine is then usually added to them. This standard treatment achieved worse results compared to SSRI/SNRI plus esketamine nasal spray: With the esketamine nasal spray, 54 percent more sufferers achieved a reduction in depression in the eighth week, and even following six months the relapse rate was lower than with the standard treatment.
“This is a good value for a group with treatment-resistant depression, i.e. a poor prognosis,” explained Prof. Dr. Andreas Reif, Director of the Clinic for Psychiatry, Psychosomatics and Psychotherapy at the University Hospital Frankfurt. The results are of great importance because those affected are more likely to attempt and complete suicide and require hospital treatment.
The study with almost 700 patients was carried out on behalf of the Janssen Pharmaceutical Companies of Johnson & Johnson at 71 hospitals, inpatient and outpatient clinics and research centers in 24 countries to determine the safety and effectiveness of esketamine nasal spray in combination with SSRI/SNRI to investigate.
Which: DOI doi.org/10.1056/NEJMoa2304145
1698390928
#Depression #Nasal #spray #works #standard #treatment
